ORG Wealth Partners LLC Buys 1,089 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

ORG Wealth Partners LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 83.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,401 shares of the biopharmaceutical company’s stock after buying an additional 1,089 shares during the period. ORG Wealth Partners LLC’s holdings in Gilead Sciences were worth $222,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at approximately $25,000. Valued Wealth Advisors LLC raised its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter valued at about $33,000. Cedar Wealth Management LLC raised its holdings in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares in the last quarter. Finally, Friedenthal Financial acquired a new position in Gilead Sciences in the 3rd quarter valued at approximately $50,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 0.2 %

Shares of GILD stock traded down $0.20 during trading hours on Friday, hitting $88.94. 2,883,444 shares of the company were exchanged, compared to its average volume of 5,201,311. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The business has a 50 day moving average of $91.93 and a two-hundred day moving average of $83.06. The company has a market capitalization of $110.84 billion, a PE ratio of 988.22, a PEG ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wells Fargo & Company upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $87.00 to $113.00 in a report on Friday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Barclays raised their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Finally, Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of Gilead Sciences stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now owns 132,373 shares of the company’s stock, valued at $12,173,021.08. The trade was a 6.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 453,734 shares of company stock valued at $41,902,086. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.